Signal transducer and activator of transcription 3 inhibitors: A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 1, 2011, Pages 65-83

  Page, Brent Dg ^a   Ball, Daniel P ^a   Gunning, Patrick T ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Anticancer drugs; Cancer therapeutics; JAK STAT pathway; Molecular therapeutics; Oncogene; Proteinprotein interactions; Stat3

Indexed keywords

CARBOPLATIN; CISPLATIN; CPA 7; CPD188; CPD3 2; CPD3 7; CPD30; CPD30 12; IS3 295; ISS610; OLIGONUCLEOTIDE; OXALIPLATIN; PROTEIN SH2; S31 2001; S31 M2001; S3I 2001; STA 21; STAT3 PROTEIN; STX 0119; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; BREAST CANCER; CELL STRAIN MCF 7; CELL VIABILITY; COLORECTAL CANCER; DIMERIZATION; DNA BINDING; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GEL MOBILITY SHIFT ASSAY; HUMAN; IC 50; MEMBRANE PERMEABILITY; NONHUMAN; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; TUMOR GROWTH; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES; PATENTS AS TOPIC; PEPTIDES; STAT3 TRANSCRIPTION FACTOR;

EID: 78650499336     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.539205     Document Type: Review

References (84)

1. Fletcher S, Turkson J, Gunning PT. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 2008;3(8):1159-68
2. Fletcher S, Drewry JA, Shahani VM, et al. Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 2009;87(6):825-33
3. Bowman T, Garcia R, Turkson J, et al. STATs in oncogenesis. Oncogene 2000;19(21):2474-88
4. Bromberg J. Stat proteins and oncogenesis. J Clin Invest 2002;109(9):1139-42
5. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98(3):295-303
6. Darnell Jr JE. STATs and gene regulation. Science 1997;277(5332):1630-5
7. Jing N, Tweardy DJ. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005;16(6):601-7
8. Berishaj M, Gao SP, Ahmed S, et al. Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer. Breast Cancer Res 2007;9:3:R32
9. Darnell Jr JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264(5164):1415-21
10. Ndubuisi MI, Guo GG, Fried VA, et al. Cellular physiology of STAT3: Where's the cytoplasmic monomer? J Biol Chem 1999;274(36):25499-509
11. Ota N, Brett TJ, Murphy TL, et al. N-domain-dependent nonphosphorylated STAT4 dimers required for cytokine-driven activation. Nat Immunol 2004;5(5):208-15
12. Braunstein J, Brutsaert S, Olson R, et al. STATs dimerize in the absence of phosphorylation. J Biol Chem 2003;278(36):34133-40
13. Darnell Jr JE. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002;2(2):740-9
14. Starr R, Willson TA, Viney EM, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387(6636):917-21
15. Chung CD, Liao J, Liu B, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science 1997;278(5344):1803-5
16. Haque SJ, Flati V, Deb A, et al. Roles of protein-tyrosine phosphatases in Stat1alpha-mediated cell signaling. J Biol Chem 1995;270(43):25709-14
17. Haspel RL, Salditt-Georgieff M, Darnell Jr JE. The rapid inactivation of nuclear tyrosine phosphorylated Stat1 depends upon a protein tyrosine phosphatase. EMBO J 1996;15(22):6262-8
18. Shuai K, Liao J, Song MM. Enhancement of antiproliferative activity of gamma interferon by the specific inhibition of tyrosine dephosphorylation of Stat1. Mol Cell Biol 1996;16(9):4932-41
19. Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 1996;273(5282):1717-19
20. Yu C-, Burakoff SJ. Involvement of proteasomes in regulating jak-STAT pathways upon interleukin-2 stimulation. J Biol Chem 1997;272(22):14017-20
21. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001;276(48):45443-55
22. Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 2004;3(3):261-9
23. Berg T. Inhibition of transcription factors with small organic molecules. Curr Opin Chem Biol 2008;12(4):464-71
24. Turkson J, Ryan D, Kim JS, et al. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 2001;276(48):45443-55
25. Yue P, Turkson J. Targeting STAT3 in cancer: how successful are we? Expert Opin Investig Drugs 2009;18(1):45-56
26. Drewry JA, Fletcher S, Yue P, et al. Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Commun 2010;46(6):892-4
27. Fletcher S, Singh J, Zhang X, et al. Disruption of transcriptionally active stat3 dimers with non-phosphorylated, salicylic acid-based small molecules: potent in vitro and tumor cell activities. ChemBioChem 2009;10(12):1959-64
28. Yu Z-, Huang R, Xiao H, et al. Fluacrypyrim, a novel STAT3 activation inhibitor, induces cell cycle arrest and apoptosis in cancer cells harboring constitutively-active STAT3. Int J Cancer 2010;127(6):1259-70
29. Okumura F, Matsunaga Y, Katayama Y, et al. TRIM8 modulates STAT3 activity through negative regulation of PIAS3. J Cell Sci 2010;123(13):2238-45
30. Nagaraj NS, Smith JJ, Revetta F, et al. Targeted inhibition of src kinase signaling attenuates pancreatic tumorigenesis. Mol Cancer Ther 2010;9(8):2322-32
31. Drewry JA, Fletcher S, Yue P, et al. Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions. Chem Commun 2010;46(6):892-4
32. Xu X, Kasembeli MM, Jiang X, et al. Chemical probes that competitively and selectively inhibit Stat3 activation. PLoS ONE 2009;4(3):e4783
33. Ren Z, Cabell LA, Schaefer TS, et al. Identification of a high-affinity phosphopeptide inhibitor of Stat3. Bioorg Med Chem Lett 2003;13(4):633-6
34. Bhasin D, Cisek K, Pandharkar T, et al. Design, synthesis, and studies of small molecule STAT3 inhibitors. Bioorg Med Chem Lett 2008;18(1):391-5
35. Song H, Wang R, Wang S, et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005;102(13):4700-5
36. Matsuno K, Masuda Y, Sato H, et al. Identification of a new series of STAT3 inhibitors by virtual screening. ACS Med Chem Lett 2010;1(8):371-5
37. Chen J, Bai L, Bernard D, et al. Structure-based design of conformationally constrained, cell-permeable Stat3 inhibitors. ACS Med Chem Lett 2010;1:85-9
38. Redell MS, Tweardy DJ. Targeting transcription factors for cancer therapy. Curr Pharm Des 2005;11(22):2873-87
39. Jove R, Dalton W, Sebti S, et al. Inhibition of Stat3 signal transuction for human cancer therapy. WO0044774; 2000
40. McMurray JS, Ren Z, Coleman DR, et al. Inhibitors of signal transduction and activator of transcription 3. US20070010428; 2007
41. Tweardy DJ. Structural requirements for Stat3 binding and recruitment to phosphotyrosine ligands. WO2006069001; 2006
42. Stahl N, Farruggella TJ, Boulton TG, et al. Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 1995;267(5202):1349-53
43. Weber-Nordtt RM, Riley JK, Greenlund AC, et al. Stat3 recruitment by two distinct ligand-induced, tyrosine-phosphorylated docking sites in the interleukin-10 receptor intracellular domain. J Biol Chem 1996;271:27954-61
44. Coleman IV DR, Ren Z, Mandal PK, et al. Investigation of the binding determinants of phosphopeptides targeted to the src homology 2 domain of the signal transducer and activator of transcription 3. development of a high-affinity peptide inhibitor. J Med Chem 2005;48(21):6661-70
45. Schust J, Berg T. A high-throughput fluorescence polarization assay for signal transducer and activator of transcription 3. Anal Biochem 2004;330(1):114-18
46. Wang S, Chen J, Zhao Y, et al. Stat3 inhibitors and therapeuic methods using the same. WO10077589; 2010
47. Sebti SM, Hamilton AD, Turkson J, et al. Use of SH2 Stat3/Stat1 peptidomimietics as anticancer drugs. WO08070833; 2008
48. Gunning PT, Katt WP, Glenn M, et al. Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: Structural recognition of STAT SH2 domains. Bioorg Med Chem Lett 2007;17(7):1875-8
49. Jones G, Willett P, Glen RC, et al. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997;267(3):727-48
50. Zhang T, Kee WH, Seow KT, et al. The coiled-coil domain of Stat3 is essential for its SH2 domain-mediated receptor binding and subsequent activation induced by epidermal growth factor and interleukin-6. Mol Cell Biol 2000;20(19):7132-9
51. Zhang X, Darnell Jr JE. Functional importance of Stat3 tetramerization in activation of the alpha2-macroglobulin gene. J Biol Chem 2001;276(36):33576-81
52. Xu X, Sun Y-, Hoey T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science 1996;273(5276):794-7
53. Timofeeva OA, Gaponenko V, Lockett SJ, et al. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biol 2007;2(12):799-809
54. Michejda CJ (deceased), Tarasova NI, Timofeeva O, et al. Peptided-based STAT inhibitor. WO08151037; 2008
55. Xu X, Sun Y-, Hoey T. Cooperative DNA binding and sequence-selective recognition conferred by the STAT amino-terminal domain. Science 1996;273(5276):794-7
56. Zhang X, Darnell Jr JE. Functional importance of Stat3 tetramerization in activation of the alpha2-macroglobulin gene. J Biol Chem 2001;276(36):33576-81
57. Ma J, Zhang T, Novotny-Diermayr V, et al. A novel sequence in the coiled-coil domain of Stat3 essential for its nuclear translocation. J Biol Chem 2003;278(31):29252-60
58. Byrd RA, Gaponenko V, Sarma SP, et al. New insights into dimerization of STAT proteins: a vehicle to modulate signaling for therapeutic purposes? (meeting abstract). Proc Amer Assoc Cancer Res 2002;43:139
59. Mae M, Langel U. Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol 2006;6(5):509-14
60. Song H, Wang R, Wang S, et al. Small molecule inhibitors of Stat3 and the uses therof. WO2006091837; 2006
61. Song H, Wang R, Wang S, et al. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 2005;102(13):4700-5
62. Becker S, Groner B, Muller CW. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998;394(6689):145-51
63. Ewing TJA, Makino S, Skillman AG, et al. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 2001;15(5):411-28
64. Turkson J, Sebti SM, Guida W, et al. Small molecule inhibitors of STAT3 with anti-tumor activity. US20090069420; 2007
65. Siddiquee K, Zhang S, Guida WC, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 2007;104(18):7391-6
66. Zhang X, Yue P, Fletcher S, et al. A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 2010;79(10):1398-409
67. Tweardy DJ, Huang X, Kasembeli MM. Stat3 inhibitors. WO09149192; 2009
68. Totrov M, Abagyan R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins: structure, function and genetics 1997;29(Suppl. 1):215-20
69. Asai A, Matsuno K, Ogo N, et al. STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient. WO10004761; 2010
70. Gunning PT, Glenn MP, Siddiquee KA, et al. Targeting protein-protein interactions: Suppression of Stat3 dimerization with rationally designed small-molecule, nonpeptidic SH2 domain binders. ChemBioChem 2008;9(17):2800-3
71. Siddiquee KAZ, Gunning PT, Glen M, et al. An oxazole-based small-molecule stat3 inhibitor modulates stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol 2007;2(12):787-98
72. Turkson J, Hamilton AD, Jove R, et al. Stat3 inhibitor having anti-cancer activity and associated methods. WO08070697; 2008
73. Grandis JR, Johnson DE, Leong P. Stat3 decoy oligonucleotides and uses therefor. WO2006012625; 2006
74. Leong PL, Andrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci USA 2003;100(7):4138-43
75. Xi S, Gooding WE, Grandis JR. In vivo antitumor efficacy of STAT3 blockade using a transcription factor decoy approach: implications for cancer therapy. Oncogene 2005;24(6):970-9
76. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119(3):493-501
77. D'Herde K, De Pestel G, Roels F. In situ end labeling of fragmented DNA in induced ovarian atresia. Biochem Cell Biol 1994;72(11-12):573-9
78. Sen M, Tosca PJ, Zwayer C, et al. Lack of toxicity of a STAT3 decoy oligonucleotide. Cancer Chemother Pharmacol 2009;63(6):983-95
79. Turkson J, Zhang S, Palmer J, et al. Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity. Mol Cancer Ther 2004;3(12):1533-42
80. Turkson J, Jove R, Palmer JW, et al. Methods for inhibiting tumor cell proliferation involving platinum complexes. EP1664070; 2006
81. Turkson J, Zhang S, Mora LB, et al. A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 2005;280(38):32979-88
82. Turkson J, Jove R, Sebti S. Platinum IV complex inhibitor. WO06071812; 2006
83. Sherry MM, Reeves A, Wu JK, et al. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009;27(10):2383-92
84. Wei J, Barr J, Kong L, et al. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 2010;9(1):67-78